The Board of Innate Immunotherapeutics Limited (“IIL” or “the Company”) has resolved to grant 500,000 options to the Company’s Chief Executive Officer, Mr. Simon Wilkinson.
The Options will have an exercise price of A$0.80 and an expiry date of 31 August 2018.
The grant of these options to Mr. Wilkinson is conditional upon the approval of shareholders which will be sought at the Company’s Annual General Meeting due to be held in Sydney on Wednesday 30 August 2017.
For further information please download PDF attached:
Download this document
